

BOARDS AND COMMISSIONS

Board of Pharmacy

(Amendment)

201 KAR 2:220. Collaborative care agreements.

RELATES TO: KRS 315.010(5), 315.121, 315.040(3), 315.191(1)(a)

STATUTORY AUTHORITY: KRS 315.191(1)(a)

NECESSITY, FUNCTION, AND CONFORMITY: KRS 315.191(1)(a) authorizes the Board of Pharmacy to promulgate administrative regulations to regulate and control matters relating to pharmacists, pharmacist interns, pharmacy technicians, pharmacies, wholesale distributors, and manufacturers. This administrative regulation establishes minimum requirements for the development and maintenance of collaborative care agreements between pharmacist and practitioner.

Section 1. A collaborative care agreement shall:

- (1) Be in writing;
- (2) Be signed and dated by:
 - (a) Each practitioner; and
 - (b) Each pharmacist who is a party to the agreement;
- (3) Provide the method for referral of patients to be managed under the agreement; and
- (4) State the method for termination of the agreement.

Section 2. The following information relating to a patient managed under the collaborative care agreement shall be maintained by the pharmacist:

- (1) Name;
- (2) Address and phone number;
- (3) Emergency notification contact;
- (4) Date of birth, weight, height, and sex;
- (5) Medical history, including:
 - (a) Known diseases;
 - (b) Known allergies;
 - (c) Reactions and conditions relating to:
 1. Prescription medications; and
 2. Nonprescription medications;
 - (d) Current prescription regimen; and
 - (e) Current nonprescription regimen;
- (6) Lab tests ordered, including results of lab tests;
- (7) Assessment of patient outcomes;
- (8) Notes relating to the care and course of therapy of the patient; and
- (9) Documentation of patient consent to receive care under the collaborative care agreement.

Section 3. Documentation relating to the care and course of therapy of the patient pursuant to the agreement shall be documented in the patient's record maintained by the pharmacist, provided to the collaborating practitioner, and be readily available to other healthcare professionals providing care to the patient.

Section 4. A collaborative care agreement shall comply with KRS 315.010(5) and contain the following information:

- (1) Protocol, criteria, standing orders, or other method by which services are authorized;
- (2) The method established for the assessment of patient outcomes, if appropriate; and
- (3) Lab tests that may be ordered.

Section 5. A collaborative care agreement and information and records required by the provisions of this administrative regulation shall be maintained:

(1) At the pharmacist's practice site; and

(2) For at least five (5) years after the termination of the agreement.

(23 Ky.R. 3125; Am. 3807; 4109; eff. 6-16-1997; 34 Ky.R. 2421; eff. 8-1-2008; 42 Ky.R.458; 1548; 1710; eff. 12-16-2015; 50 Ky.R. 2091; eff. 10-23-2024.)

CHRISTOPHER HARLOW, Pharm.D., Executive Director

APPROVED BY AGENCY: February 19, 2024

FILED WITH LRC: February 20, 2024 at 11:15 a.m.

PUBLIC HEARING AND COMMENT PERIOD: A public hearing on this administrative regulation shall be held on May 22, 2024, at 10:00 a.m. Eastern Time at 125 Holmes Street, Frankfort, Kentucky 40601 and via teleconference. Individuals interested in being heard at this hearing shall notify this agency in writing by five workdays prior to the hearing, of their intent to attend. If no notification of intent to attend the hearing is received by that date, the hearing may be canceled. This hearing is open to the public. Any person who wishes to be heard will be given an opportunity to comment on the proposed administrative regulation. A transcript of the public hearing will not be made unless a written request for a transcript is made. If you do not wish to be heard at the public hearing, you may submit written comments on the proposed administrative regulation. Written comments shall be accepted through May 31, 2024. Send written notification of intent to be heard at the public hearing or written comments on the proposed administrative regulation to the contact person.

CONTACT PERSON: Christopher Harlow, Executive Director, Kentucky Board of Pharmacy, 125 Holmes Street, Suite 300, State Office Building Annex, Frankfort, Kentucky 40601, phone (502) 564-7910, fax (502) 696-3806, email Christopher.harlow@ky.gov.